Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US11142750B2 · kind B2 · utility
3Cited by
20References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2019 |
| Grant date | Oct 12, 2021 |
| Priority date | — |
| Expiry date | Jul 31, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to the first-generation meganuclease HBV 11-12×.26. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.